Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Targeting Mutant IDH to Treat Low-grade Glioma
touchIN CONVERSATION
Start Learning
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
Durvalumab + tremelimumab vs. doxorubicin in soft tissue sarcoma – MEDISARC study: Viktor Grünwald, ESMO 2023
touchMEETING HIGHLIGHTS
Start Learning
A voyage of discovery: Exploring the latest evidence for 1q21+
Sponsored content
JOURNALS
Start Learning
Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients
JOURNALS
Start Learning
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023
touchEXPERT BRIEFING
Start Learning
Front-line consolidation therapy in B-ALL: current challenges and novel strategies
Sponsored content
touchPANEL DISCUSSION
Start Learning
New and emerging agents in HER2-negative metastatic breast cancer: Implications for current and future practice
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
Highlights in gynaecological oncology: Domenica Lorusso, ESMO 2023
JOURNALS
Start Learning
Foreword – touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024

to view Favourites, Keep Notes and Track CME Credits

Favourites
New horizons in R/R follicular lymphoma: Focus on risk stratification and managing the practicalities of CAR T-cell therapy
View
Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab
View
2024 ASCO Annual Meeting, May 31 – June 4, McCormick Place • Chicago, IL
View
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023
View
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
View
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
View
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
View
Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer
View
Current and future considerations for the use of immune checkpoint inhibitors in non-small cell lung cancer
View
Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72